OPTIC TRACT NEUROPATHY COMPLICATING LOW-DOSE INTERFERON TREATMENT

被引:40
|
作者
MANESIS, EK [1 ]
PETROU, C [1 ]
BROUZAS, D [1 ]
HADZIYANNIS, S [1 ]
机构
[1] HIPPOCRAT GEN HOSP,DEPT OPHTHALMOL,ATHENS,GREECE
关键词
INTERFERON NEUROTOXICITY; OCULAR COMPLICATIONS OF INTERFERON; TOXIC OPTIC NEURITIS;
D O I
10.1016/S0168-8278(05)80331-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Optic neuritis occurred in three of our patients receiving treatment with alpha interferon-2b (Intron-A; 3MU thrice weekly) for chronic hepatitis. The complication appeared within, 1, 91/2 and 10 months of treatment, respectively. In all cases, blurred vision was the initial complaint and subsequent electrophysiologic investigation confirmed the presence of optic tract neuropathy. The patients had no other neurologic signs. Computerized tomography and magnetic resonance image of the brain were not remarkable. Psychiatric symptoms, in the form of an interferon-associated depressive reaction, were present in two of them; in one case, it was severe enough to require immediate discontinuation of treatment. In two patients the visual symptoms resolved and the parameters of neurophysiologic testing returned to normal within 1 month after stopping interferon. In one case, however, residual optic tract impairment associated with a unilateral central scotoma and a substantial decrease of visual acuity was present 2 years later, despite a course of methylprednizolone. In this patient the interferon treatment was continued for 3 months despite the visual symptoms, and he later received two additional interferon courses because of relapses of hepatitis. We conclude that clinically evident optic tract neuropathy may complicate interferon administration. Candidates for interferon treatment may need routine examination of optic fields and visual evoked potentials, before and during administration of the drug to avoid possibly permanent visual sequelae. (C) Journal of Hepatology.
引用
收藏
页码:474 / 477
页数:4
相关论文
共 50 条
  • [31] Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy
    Cox, April Ann
    Sagot, Yves
    Hedou, Gael
    Grek, Christina
    Wilkes, Travis
    Vinik, Aaron I.
    Ghatnekar, Gautam
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
  • [32] PNEUMOCYSTIS-CARINII PNEUMONIA COMPLICATING LOW-DOSE METHOTREXATE TREATMENT FOR RHEUMATOID-ARTHRITIS
    WOLLNER, A
    MOHLEBOETANI, J
    LAMBERT, RE
    PERRUQUET, JL
    RAFFIN, TA
    MCGUIRE, JL
    THORAX, 1991, 46 (03) : 205 - 207
  • [33] PNEUMOCYSTIS-CARINII PNEUMONIA COMPLICATING LOW-DOSE METHOTREXATE TREATMENT FOR RHEUMATOID-ARTHRITIS
    HOUTMAN, PM
    STENGER, AAME
    PASMA, HR
    SPOELSTRA, P
    BRITISH JOURNAL OF RHEUMATOLOGY, 1992, 31 : 34 - 34
  • [34] PNEUMOCYSTIS-CARINII PNEUMONIA COMPLICATING LOW-DOSE METHOTREXATE TREATMENT FOR RHEUMATOID-ARTHRITIS
    MARSHALL, D
    STURROCK, RD
    PORTER, D
    CAPELL, HA
    THORAX, 1992, 47 (01) : 67 - 67
  • [35] Pneumonitis complicating low dose methotrexate treatment
    Salouage, I
    Tekaya, R
    El Aïdli, S
    Kastalli, S
    Meddeb, N
    Daghfous, R
    Lakhal, M
    Loueslati, MH
    Sellami, S
    Belkahia, CH
    DRUG SAFETY, 2005, 28 (10) : 954 - 954
  • [36] SEIZURES ASSOCIATED WITH LOW-DOSE ALPHA-INTERFERON
    JANSSEN, HLA
    BERK, L
    VERMEULEN, M
    SCHALM, SW
    LANCET, 1990, 336 (8730): : 1580 - 1580
  • [37] ISCHEMIC OPTIC NEUROPATHY COMPLICATING CARDIOPULMONARY BYPASS
    LARKIN, DFP
    WOOD, AE
    NELIGAN, M
    EUSTACE, P
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1987, 71 (05) : 344 - 347
  • [38] Low-dose oral alpha interferon study opens
    不详
    AIDS PATIENT CARE AND STDS, 1996, 10 (04) : 264 - 264
  • [39] Optic neuropathy complicating multifocal choroiditis and panuveitis
    Thorne, Jennifer E.
    Wittenberg, Susan
    Kedhar, Sanjay R.
    Dunn, James P.
    Jabs, Douglas A.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (04) : 721 - 723
  • [40] TREATMENT OF RENAL-CELL CARCINOMA WITH DAILY LOW-DOSE ALPHA-INTERFERON
    MARSHALL, ME
    SIMPSON, W
    BUTLER, K
    FRIED, A
    FER, M
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1989, 8 (05): : 453 - 461